| Description | RORγt Inverse agonist 6 is an agonist of RORγt inverse. RORγt Inverse agonist 6 can be used in research on Th17-driven autoimmune diseases. |
| In vivo | RORγt Inverse agonist 6 （30 mg/kg；口服）在经口给药后与溶剂对照组相比，能抑制IL-17A的表达水平59%。同样，在小鼠药效学模型中，RORγt Inverse agonist 6 能抑制IL-23刺激下IL-17A基因的表达。此外，RORγt Inverse agonist 6 （1 mg/kg；口服）展示了改善的化合物暴露度，其AUC为1289 ng h/mL[1]。 |
| molecular weight | 565.02 |
| Molecular formula | C28H29ClN6O5 |
| CAS | 1887161-80-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (79.64 mM), Sonication is recommended. |
| References | 1. Sato A, et al. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists. ChemMedChem. 2019 Oct 28. |